Inflammation- and Gut-Homing Macrophages, Engineered to De Novo Overexpress Active Vitamin D, Promoted the Regenerative Function of Intestinal Stem Cells

Inflammatory bowel disease (IBD) is a chronic inflammatory disease of the gut. Available drugs aim to suppress gut inflammation. These drugs have significantly delayed disease progression and improved patients' quality of life. However, the disease continues to progress, underscoring the need to develop novel therapies. Aside from chronic gut inflammation, IBD patients also experience a leaky gut problem due to damage to the intestinal epithelial layer. In this regard, epithelial regeneration and repair are mediated by intestinal stem cells. However, no therapies are available to directly enhance the intestinal stem cells' regenerative and repair function. Recently, it was shown that active vitamin D, i.e., 1,25-dihydroxyvitamin D or 1,25(OH)(2)D, was necessary to maintain Lgr5(+) intestinal stem cells, actively cycling under physiological conditions. In this study, we used two strategies to investigate the role of 1,25(OH)(2)D in intestinal stem cells' regenerative function. First, to avoid the side effects of systemic high 1,25(OH)(2)D conditions, we used our recently developed novel strategy to deliver locally high 1,25(OH)(2)D concentrations specifically to inflamed intestines. Second, because of the Lgr5(+) intestinal stem cells' active cycling status, we used a pulse-and-chase strategy via 5-bromo-2 '-deoxyuridine (BrdU) labeling to trace the Lgr5(+) stem cells through the whole epithelial regeneration process. Our data showed that locally high 1,25(OH)(2)D concentrations enhanced intestinal stem cell migration. Additionally, the migrated cells differentiated into mature epithelial cells. Our data, therefore, suggest that local delivery of high 1,25(OH)(2)D concentrations is a promising strategy to augment intestinal epithelial repair in IBD patients.

Automated summary

Inflammatory bowel disease (IBD) is a chronic inflammatory disease affecting the gut. Current drugs aim to suppress inflammation but novel therapies are needed as the disease progresses. Alongside chronic gut inflammation, IBD patients also suffer from a leaky gut issue, with no current treatments to enhance intestinal stem cell regeneration and repair.